Interrupting immune-suppressing therapies in vulnerable people doubles their antibody response to COVID-19 booster vaccination, the findings of a new study suggest.

The open-label, prospective, randomised controlled trial recruited adults with autoimmune inflammatory conditions attending rheumatology and dermatology clinics at 26 hospitals in the United Kingdom. All participants were taking low-dose...